Introduction
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7), and the 2006 NICE guidelines note that most subjects with hypertension require two or more anti-hypertensive medications to achieve their blood pressure (BP) goals. 1, 2 Compliance with JNC 7 guidelines requires that if BP is persistently 420 mm Hg above systolic goal (or 410 mm Hg above diastolic goal), therapy should be initiated using at least two drugs, either as separate prescriptions or as fixed-dose (single-pill) combinations because when BP control is delayed or lost, there are more cardiovascular events. 1, 3, 4 In addition, different combinations of anti-hypertensive drugs can have differing effects on cardiovascular outcomes even if the blood pressure effects are equivalent. In the ACCOMPLISH study (Avoiding Cardiovascular Events in Combination Therapy in Patients Living with Systolic Hypertension), in high-risk patients, the combination of amlodipine and benazepril caused a 20% relative risk reduction in cardiovascular event rates compared with hydrochlorothiazide/benazepril. 5 This study was designed to determine whether BP control could be achieved within 6 weeks in subjects with stage 2 hypertension using two end point-limited titration algorithms: one using initial amlodipine (5 mg and 10 mg per day) monotherapy and the other using initial combination therapy of amlodipine (5 and 10 mg per day) with angiotensinconverting enzyme inhibitor benazepril (20 and 40 mg daily).
Methods
Subjects Study participants were men and women aged 18-80 years with severe systolic blood pressure; SBP X180 and p210 mm Hg (or X170 and p210 mm Hg in subjects with diabetes or chronic kidney disease, CKD) or diastolic blood pressure, DBP X110 and p120 mm Hg (or X100 and p120 mm Hg in subjects with diabetes or CKD).
Patients with mean sitting DBP o60 mm Hg, SBP X180 mm Hg and/or DBP X110 mm Hg, and unresponsive to triple-drug regimens or receiving maximum dose of angiotensin converting enzyme inhibitor and calcium-channel blocker combination therapy were excluded. Furthermore, patients were also excluded if they had secondary hypertension; clinically significant cardiac arrhythmias; recent history (o6 months of randomization) of myocardial infarction, angina pectoris, stroke or transient ischemic attack, or cardiovascular revascularization; evidence of heart failure, or a documented left ventricular ejection fraction o40%, evidence of hepatic, pancreatic, or renal impairment and use of insulin. Women who were pregnant, nursing, or had child-bearing potential and who were not using an acceptable method of contraception were also excluded. Use of non-steroidal anti-inflammatory drugs and Cox-2 inhibitors was allowed on an asneeded basis with instructions to withhold the use 24 h before the scheduled BP measurement. Use of aspirin (p325 mg daily) or phosphodiesterase type-5 inhibitors for erectile dysfunction was allowed, with instructions to withhold the use of sildenafil 24 h before and vardenafil hydrochloride 48 h before the BP measurement.
Written informed consents were obtained from all subjects before their inclusion in the study. The protocol was approved by the institutional review board of each study centre. The study was conducted in accordance with the ethical principles of the current Declaration of Helsinki.
Study design
This multicentre, randomized, double-blind, parallel group titration study that lasted up to 6 weeks in each subject was performed at 33 centres across the United States. After a 1-4-week, single-blind placebo run-in period, eligible subjects were randomized to receive fixed-dose (single-pill) combination amlodipine/benazepril therapy (A/B; 5/20 mg) or amlodipine monotherapy (A; 5 mg daily) for 2 weeks. At the end of Week 2, non-responders (target BP o140/ 90 mm Hg or o130/80 mm Hg in subjects with diabetes or CKD) were up-titrated to A/B (10/ 20 mg) or A (10 mg) (Level 2) for additional 2 weeks. Responders were maintained on dose level A/B (5/20 mg) or A (5 mg) (Level 1) until the end of the study. At the end of Week 4, non-responders in the A/B group were further up-titrated to A/B (10/40 mg) (Level 3) or those in the A group were sham-titrated with A (10 mg) for 2 weeks, whereas responders were maintained on dose Level 2 ( Figure 1 ). In this end point-limited dosing study, only subjects not meeting the BP goal at each dose level were uptitrated to the next dose level. Back-titration to the previous dose level was not permitted. Subjects were instructed to take their medications at the same time each morning. Every attempt was made to reinitiate therapy at the previous dosing level if a brief interruption of study medication occurred; lapses of more than a week resulted in termination from the trial. Concomitant administration of drugs likely to affect BP, as well as those likely to interact with study medication, was prohibited throughout the study.
Blood pressure determination
At each visit, blood pressure was measured using an OMRON automatic BP monitoring device (Omron Healthcare, Bannockburn, IL, USA) with an appropriate sized cuff. The clinic BP reference value for each subject was the average of three serial measurements taken at 2-min intervals after the subject had rested for 5 min in the sitting position.
Statistical analysis
Trended analyses of BP responses and control rates at Week 2, 4 and 6 using analysis of covariance with baseline measurement, stratum and treatment as covariates was conducted. All statistical tests were conducted against a two-sided alternative hypothesis, using a significance level of 0.05. Sample-size calculation was based on the anticipated trended BP control-rate difference between treatment arms. Assuming that (1) the expected percentages of subjects achieving BP goal by the end of the study were 29 and 10% for the A/B and A treatment arms, respectively, and (2) the dropout rate would be 25%, it was determined that the study should include at least 268 subjects (134 in each group) to provide a 90% power to detect a significance (two-sided test, a ¼ 0.05). Background and demographic variables were summarized using descriptive statistics. The w 2 test was used for analyzing categorical variables and two-sample t-test was used for continuous variables to test for homogeneity between treatment groups. All randomized subjects, who received at least one dose of the study medication and had one valid post-baseline assessment of the primary efficacy variable, were included in the efficacy and safety analyses (intent-to-treat population). In case of missing data, the last-observation-carried-forward approach was used to obtain the last post-baseline assessment.
Sub-group analyses were performed for gender, age, race, presence or absence of diabetes or CKD, and various treatment-dose levels. Safety and tolerability were also assessed for each treatment arm by measuring and recording any new symptoms, physical signs (including oedema), changes in hematology, changes in blood or urine chemistries or electrocardiographic abnormalities.
Results
A total of 351 subjects were enroled in the study, 259 of whom completed the single-blind placebo run-in period and were randomized to the double-blind treatment period (129 subjects in the A/B group, 130 subjects in the A group). The most common reasons for subject ineligibility for randomization were: not meeting inclusion criteria for the diagnosis of severe hypertension and withdrawal of consent by the subject. Figure 2 outlines subject enrolment and disposition. Baseline characteristics of the study population are summarized in Table 1 . The two groups were comparable in terms of age, sex, body weight, gender race and baseline blood pressure. At least 72% of subjects in each treatment group were o65 years of age. As typical for this subject population, the mean body mass index for each treatment group was within the obese range (A/B: 32.4 kg m À2 ; A: 33.8 kg m À2 ). Mean sitting SBP at baseline ranged from 133.0 to 218.0 mm Hg (overall mean: 175.7 mm Hg) and mean sitting DBP ranged from 66.0 to 120 mm Hg (overall mean: 99.6 mm Hg). The overall proportion of subjects with peripheral oedema at baseline was 13%. At least one-fourth of enroled patients in each treatment group had diabetes or CKD at baseline. At the end of study, at least 75% of the enroled subjects were on dose level 3 (A/B 10/40 mg; A 10 mg).
Changes in mean SBP and mean DBP from baseline Significantly larger decreases in SBP were observed at all weeks in the A/B group than in the A group respectively, and at Week 6, the goal rates increased to 43% in the A/B group and to 29% in the A group (P ¼ 0.02). Almost 75% of patients in both treatment groups were at dose level 3 at the end of the study (Table 1) . Of the patients receiving dose level 1 or dose level 2 at the end of the study, a higher proportion of them achieved the BP goal at Week 4 in the A/B group compared with the A group. However, these differences were not statistically significant.
Sub-group analysis
Among the patients aged o65 years, the differences between treatment groups in mean change from baseline in SBP were statistically significant in the favour of A/B regimen at Week 2 (À21. Combination therapy A/B was more effective than A monotherapy regardless of the patient's sex. Except for African Americans, there were no statistically significant differences between treatment groups for any other race subgroup at Week 2 or for any race subgroup at Weeks 4 or 6. In African Americans at Week 2, the treatment response was significantly in favour of the A/B regimen (20% (4/20) A/B versus 0% (0/18) A; Po0.05).
Among patients with diabetes or chronic renal disease, 6.1% of A/B-treated patients and 8.8% of Atreated patients achieved the BP goal at Week 4; and among patients without diabetes or chronic renal disease, 27.4% of A/B-treated patients and 19.1% of A-treated patients achieved the BP goal at Week 4.
Adverse events
The adverse events were generally mild or moderate, transient, and did not appear to be treatment related (Table 2) . Overall, 128 (49.4%) of the 259 patients in the safety population experienced at least 1 adverse event: 65 (50.4%) in the A/B group and 63 (48.5%) in the A group. The most frequently reported adverse events were peripheral oedema, headache, cough, upper respiratory-tract infection, fatigue, nasopharyngitis, diarrhoea, dizziness and muscle cramp. The incidence of cough was higher in the A/ B group (7.8 versus 3.8% in the A group), whereas the incidence of headache was higher in the A treatment group (7.7 versus 4.7% in the A/B group).
At baseline, 14% of the patients in the A/B group and 11.5% of the A group had peripheral oedema. At least 75% of patients in each treatment group had no change in their baseline status of peripheral oedema at each visit. A lower cumulative proportion of patients in A/B group had peripheral oedema at Week 4 and Week 6 (13.3 and 19.5%, respectively) compared with the A monotherapy group (19.5 and 21.9%, respectively) (P ¼ 0.1759, Week 4; P ¼ 0.6377, Week 6). A total of 18 (6.9%) of the 259 patients in the safety population experienced adverse events (AEs) or serious AEs leading to discontinuation from the study: 8 in the A/B group and 10 in the A group. Three of these were serious AEs including one patient in the A/B group (cerebrovascular accident) and two in the A group (supraventricular tachycardia and worsening coronary artery disease). The most common AEs causing withdrawal were cough, peripheral oedema, and cardiac or vascular disorders, including hypotension, ischaemic chest pain and palpitations. Most of these AEs were suspected of being treatment related.
No clinically relevant changes were seen in vital signs or laboratory measurements.
Discussion
In severe hypertension, in which the most critical hemodynamic characteristic is severe vasoconstriction, effective BP control almost always requires the use of an arteriolar vasodilator such as amlodipine. In this study population with severe hypertension, although previous studies had suggested that a highly favourable drop in BP could be achieved with either A monotherapy or combination therapy with amlodipine/angiotensin converting enzyme inhibitor, 3, 5 it was unclear if full BP control (BP o140/90 mm Hg or o130/80 for subjects with diabetes or CKD) could be achieved within 6 weeks. The objective of this trial was to determine whether BP control with first-line combination therapy with amlodipine/ angiotensin converting enzyme inhibitor was superior to amlodipine alone in trended analyses of BP responses and control rates. We identified a substantial effect of A therapy (B25/11 mm Hg) and an additional BP lowering (B5/3 mm Hg) attributable to the combination of amlodipine and benazapril. The observation that BP control rates in this study are lower than those reported in other studies, 6, 7 owes, at least in part, to the very high baseline SBP and DBP measurements that were present (about 175/100 mm Hg); thus, a mean decrease in SBP of 435 mm Hg and DBP of 420 mm Hg would have been necessary to achieve BP control in the majority of subjects. More important is the strict guideline-based definition of BP control that was used (o140/90 in general or o130/80 mm Hg in subjects with diabetes or CKD). We have found only two studies with limited similarity: SOLACE by Jamerson et al. 6 and SHIELD by Bakris et al., 7 in which BP control rates were 61 and 63%, respectively. Each of these studies was of 12 weeks in duration, whereas our study was much shorter (6 weeks). In SHIELD, the time required to achieve a slightly less rigorous treatment goal (o130/85 mm Hg) was 5.3 weeks; hence in our study, a longer duration of treatment may have improved goal rates. In SOLACE, baseline BP measurements were noticeably lower (167/99 mm Hg) and the study did not include large number of patients with diabetes or CKD, whereas in SHIELD, patients were diabetic but their baseline BP measurements were substantially lower (156/97 mm Hg) than those of our study group.
Sub-group analyses showed a trend in favour of a greater response to A/B regimen among patients o65 years of age and those without diabetes or CKD, regardless of gender or dose. Taken together, the higher pre-treatment BP levels and the relatively high prevalence of diabetes and CKD directly imply that our group had more severe hypertensive cardiovascular disease that was intrinsically more difficult to control. The relatively low BP control rate (o50%) with A/B regimen, although higher than that with A monotherapy, suggests that higher doses, additional drugs or more vigorous lifestyle modifications are necessary. For patients with diabetes or CKD, three or more drugs are required to achieve the advanced BP target of o130/80 mm Hg, 1 and it is widely believed that diuretic therapy should be part of the regimen. Nevertheless, our results remain consistent with guidelines and expert recommendations that firstline combination therapy is required in Stage 2 hypertension and beyond.
Safety and tolerability is a critical consideration in hypertension management. In this study, A/B combination therapy was well tolerated and appeared to have a safety profile similar to A monotherapy. This observation should serve to quell some of the fears of practitioners that initial combination therapy is likely to cause more problems than monotherapy. Peripheral oedema is a common side effect of amlodipine and is associated with increased doses of amlodipine. 8 Although not statistically significant, the proportion of patients in the combination A/B group with peripheral oedema was smaller than that in the A monotherapy group.
In conclusion, combination therapy using amlodipine and benazepril as first-line treatment in individuals with severe hypertension is more effective than A monotherapy and is well tolerated.
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